Clene Reports First Quarter 2023 Financial Results and
ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May ...
Source: globenewswire.com
Relapsing Multiple News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Relapsing Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Relapsing Multiple Today - Breaking & Trending Today
Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor Is Safe, Clinically Effective in MS
Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.
Source: ajmc.com
Tolebrutinib 96-Week MRI Results Promising for the Investigational BTK Inhibitor
Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.
Source: ajmc.com
Janelle Annalee Cruz
Janelle Annalee Cruz, Staff Sergeant (Retired) 41 of Whittaker Road, Carthage, passed away after a yearlong courageous battle with cancer on Saturday, November 12, 2022, at Samaritan Medical Center in
Source: nny360.com
Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3
Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.
Source: europeanpharmaceuticalreview.com